Tremfya 100 mg Solution for injection in pre-filled syringe
PDF Leaflet Revision Date: 6 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Dosage (summary)
100 mg SC at week 0, week 4, then every 8 weeks; for psoriatic arthritis, consider every 4 weeks for high-risk patients.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment.
Key Drug Interactions
- Live vaccines
- CYP450 substrates
Contraindications
- Hypersensitivity to guselkumab
- Active infections
- Active tuberculosis
Common side effects
- Respiratory tract infections
- Headache
- Diarrhoea
- Injection site reactions
Counselling Points
- Seek medical advice for signs of infection
- Complete immunisations before starting therapy
- Do not use live vaccines
Serious warnings
- Increased risk of infections
- Serious hypersensitivity reactions
Important Disclaimer
The Tremfya 100 mg Solution for injection in pre-filled syringe professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
